United States

Respirogen™ Lipid Oxygen Microbubble (OMB) technology provides novel systemic oxygen delivery to the body independent of the lungs. Hypoxia (low oxygen saturation) in lung injury patients can quickly lead to irreversible organ damage or death. OMB will reduce risk and cost of current ventilator and ECMO therapies.

Presenter: Robert Scribner, CEO, Respirogen, Inc.